Evidence map›Paper›PMID 27613501›Full record

ReviewMatrix biology : journal of the International Society for Matrix Biology2017

A current view of perlecan in physiology and pathology: A mosaic of functions.

Maria A Gubbiotti, Thomas Neill, Renato V Iozzo

Open access · greenAbstract readReview
In one paragraph

Review in Matrix biology : journal of the International Society for Matrix Biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 1 synthesis or guideline pooled it, 204 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Observational
  5. Early Post‑Traumatic Osteoarthritis Features Greater Cartilage Extracellular Matrix Proteoglycan Loss Compared to the Pericellular Matrix.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026
    Article
  6. Schwartz-Jampel Syndrome Type 1: Compound Heterozygosity of Two Novel VariantsJournal of clinical research in pediatric endocrinology · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Basement membranes at a glance.Journal of cell science · 2025
    Review
  11. Brain vascular basement membrane: Comparison of human and mouse brain at the transcriptomic and proteomic levels.Matrix biology : journal of the International Society for Matrix Biology · 2025
    Article
  12. Article
  13. Article
  14. The endothelium at the interface between tissues andClinical microbiology reviews · 2025
    Review
  15. Critical Roles of SEA Domains.Advances in experimental medicine and biology · 2025
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Maria A GubbiottiDepartment of Pathology, Anatomy, and Cell Biology and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.
Thomas NeillDepartment of Pathology, Anatomy, and Cell Biology and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.
Renato V IozzoDepartment of Pathology, Anatomy, and Cell Biology and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States. Electronic address: renato.iozzo@jefferson.edu.
Thomas Jefferson University · US

Funding

Alcohol Tissue InjuryT32AA007463 · NIAAA · THOMAS JEFFERSON UNIVERSITY · PI HOEK, JOANNES B, VADIGEPALLI, RAJANIKANTH · 1985 to 2021
$9.1M
NEOPLASTIC MODULATION OF PROTEOGLYCAN METABOLISMR01CA039481 · NCI · UNIVERSITY OF PENNSYLVANIA · PI IOZZO, RENATO V. · 1985 to 2020
$7.1M
The Biology of Perlecan in Cancer and AngiogenesisR01CA047282 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 1990 to 2019
$5.7M
Progranulin signaling in bladder cancerR01CA164462 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V., MORRIONE, ANDREA · 2012 to 2016
$1.6M
Natural EGFR Antagonists and CancerR01CA120975 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 2007 to 2010
$942k
TRAINING IN MOLECULAR DERMATOLOGY AND CUTANEOUS CONNECTIVE TISSUE DISEASEST32AR060715 · NIAMS · THOMAS JEFFERSON UNIVERSITY · PI UITTO, JOUNI · 2011 to 2015
$728k
NCI NIH HHS R01 CA039481NCI NIH HHS R01 CA047282NCI NIH HHS R01 CA120975NCI NIH HHS R01 CA164462NIAAA NIH HHS T32 AA007463NIAMS NIH HHS T32 AR060715
6 · The paper itself

Abstract

Perlecan, a large basement membrane heparan sulfate proteoglycan, is expressed in a wide array of tissues where it regulates diverse cellular processes including bone formation, inflammation, cardiac development, and angiogenesis. Here we provide a contemporary review germane to the biology of perlecan encompassing its genetic regulation as well as an analysis of its modular protein structure as it pertains to function. As perlecan signaling from the extracellular matrix converges on master regulators of autophagy, including AMPK and mTOR, via a specific interaction with vascular endothelial growth factor receptor 2, we specifically focus on the mechanism of action of perlecan in autophagy and angiogenesis and contrast the role of endorepellin, the C-terminal fragment of perlecan, in these cellular and morphogenic events.

Indexed as

AMP-Activated Protein KinasesAnimalsAutophagyBasement MembraneGene Expression RegulationHeartHeparan Sulfate ProteoglycansHumansInflammationNeovascularization, PhysiologicOrganogenesisOsteogenesisPeptide FragmentsProtein DomainsSignal TransductionTOR Serine-Threonine KinasesAMP-Activated Protein KinasesHeparan Sulfate ProteoglycansKDR protein, humanMTOR protein, humanPeptide FragmentsperlecanTOR Serine-Threonine KinasesVascular Endothelial Growth Factor Receptor-2AngiogenesisAutophagyEndorepellinHeparan sulfateProteoglycan

Identifiers

PMID27613501
PMCPMC5328851
OpenAlexW2511273639

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.